These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 37831763)

  • 1. Thrombospondin-1 proteomimetic polymers exhibit anti-angiogenic activity in a neovascular age-related macular degeneration mouse model.
    Choi W; Nensel AK; Droho S; Fattah MA; Mokashi-Punekar S; Swygart DI; Burton ST; Schwartz GW; Lavine JA; Gianneschi NC
    Sci Adv; 2023 Oct; 9(41):eadi8534. PubMed ID: 37831763
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aflibercept for neovascular age-related macular degeneration.
    Sarwar S; Clearfield E; Soliman MK; Sadiq MA; Baldwin AJ; Hanout M; Agarwal A; Sepah YJ; Do DV; Nguyen QD
    Cochrane Database Syst Rev; 2016 Feb; 2(2):CD011346. PubMed ID: 26857947
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-life management of neovascular age-related macular degeneration (nAMD) in France: a nationwide observational study using retrospective claims data.
    Korobelnik JF; Delcourt C; Creuzot-Garcher C; Melaine A; Chassetuillier J; Lejeune A; Bénard S; Dupont-Benjamin L
    J Med Econ; 2021; 24(1):1087-1097. PubMed ID: 34420480
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment regimens for administration of anti-vascular endothelial growth factor agents for neovascular age-related macular degeneration.
    Li E; Donati S; Lindsley KB; Krzystolik MG; Virgili G
    Cochrane Database Syst Rev; 2020 May; 5(5):CD012208. PubMed ID: 32374423
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aflibercept versus Faricimab in the Treatment of Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema: A Review.
    Liberski S; Wichrowska M; Kocięcki J
    Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012690
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Visual acuity outcomes of anti-VEGF treatment for neovascular age-related macular degeneration in clinical trials.
    Yamashiro K; Oishi A; Hata M; Takahashi A; Tsujikawa A
    Jpn J Ophthalmol; 2021 Nov; 65(6):741-760. PubMed ID: 34491474
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-World Effectiveness and Real-World Cost-Effectiveness of Intravitreal Aflibercept and Intravitreal Ranibizumab in Neovascular Age-Related Macular Degeneration: Systematic Review and Meta-Analysis of Real-World Studies.
    Carrasco J; Pietsch GA; Nicolas MP; Koerber C; Bennison C; Yoon J
    Adv Ther; 2020 Jan; 37(1):300-315. PubMed ID: 31728825
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of intravitreal aflibercept in ranibizumab-refractory patients with neovascular age-related macular degeneration.
    Razavi S; Kodjikian L; Giocanti-Aurégan A; Dufour I; Souied E
    BMC Ophthalmol; 2021 Feb; 21(1):90. PubMed ID: 33596867
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-world outcomes of anti-VEGF therapy in treatment-naïve neovascular age-related macular degeneration diagnosed on OCT angiography: the REVEAL study.
    Lupidi M; Schiavon S; Cerquaglia A; Fruttini D; Gujar R; Muzi A; Fiore T; Reibaldi M; Chhablani J; Cagini C
    Acta Ophthalmol; 2022 Jun; 100(4):e936-e942. PubMed ID: 34407298
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Baseline characteristics and progression of neovascular age-related macular degeneration in patients receiving over 60 intravitreal injections of anti-vascular endothelial growth factor.
    Prahs P; Brandl C; Helbig H; Volz C
    Rom J Ophthalmol; 2023; 67(3):260-266. PubMed ID: 37876508
    [No Abstract]   [Full Text] [Related]  

  • 11. Inflammatory Factors of Macular Atrophy in Eyes With Neovascular Age-Related Macular Degeneration Treated With Aflibercept.
    Sato T; Enoki T; Karasawa Y; Someya H; Taguchi M; Harimoto K; Takayama K; Kanda T; Ito M; Takeuchi M
    Front Immunol; 2021; 12():738521. PubMed ID: 34721402
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-vascular endothelial growth factor for neovascular age-related macular degeneration.
    Solomon SD; Lindsley K; Vedula SS; Krzystolik MG; Hawkins BS
    Cochrane Database Syst Rev; 2019 Mar; 3(3):CD005139. PubMed ID: 30834517
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emerging therapeutic strategies for unmet need in neovascular age-related macular degeneration.
    Khachigian LM; Liew G; Teo KYC; Wong TY; Mitchell P
    J Transl Med; 2023 Feb; 21(1):133. PubMed ID: 36810060
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimizing Anti-VEGF Treatment Outcomes for Patients with Neovascular Age-Related Macular Degeneration.
    Wykoff CC; Clark WL; Nielsen JS; Brill JV; Greene LS; Heggen CL
    J Manag Care Spec Pharm; 2018 Feb; 24(2-a Suppl):S3-S15. PubMed ID: 29383980
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neovascular age-related macular degeneration: intraocular cytokines and growth factors and the influence of therapy with ranibizumab.
    Funk M; Karl D; Georgopoulos M; Benesch T; Sacu S; Polak K; Zlabinger GJ; Schmidt-Erfurth U
    Ophthalmology; 2009 Dec; 116(12):2393-9. PubMed ID: 19815292
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Short-term choroidal vascular changes after aflibercept therapy for neovascular age-related macular degeneration.
    Pellegrini M; Bernabei F; Mercanti A; Sebastiani S; Peiretti E; Iovino C; Casini G; Loiudice P; Scorcia V; Giannaccare G
    Graefes Arch Clin Exp Ophthalmol; 2021 Apr; 259(4):911-918. PubMed ID: 33048236
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multimodal imaging based biomarkers predictive of early and late response to anti-VEGFs during the first year of treatment for neovascular age-related macular degeneration.
    Tarakcioglu HN; Ozkaya A; Kemer B; Taskapili M
    J Fr Ophtalmol; 2019 Jan; 42(1):22-31. PubMed ID: 30578008
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intraocular and systemic inflammation-related cytokines during one year of ranibizumab treatment for neovascular age-related macular degeneration.
    Fauser S; Viebahn U; Muether PS
    Acta Ophthalmol; 2015 Dec; 93(8):734-8. PubMed ID: 26016605
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Twenty Years of Anti-Vascular Endothelial Growth Factor Therapeutics in Neovascular Age-Related Macular Degeneration Treatment.
    Moon BH; Kim Y; Kim SY
    Int J Mol Sci; 2023 Aug; 24(16):. PubMed ID: 37629185
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-vascular endothelial growth factor in neovascular age-related macular degeneration - a systematic review of the impact of anti-VEGF on patient outcomes and healthcare systems.
    Finger RP; Daien V; Eldem BM; Talks JS; Korobelnik JF; Mitchell P; Sakamoto T; Wong TY; Pantiri K; Carrasco J
    BMC Ophthalmol; 2020 Jul; 20(1):294. PubMed ID: 32680477
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.